Anixa BiosciencesANIX
About: Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
Employees: 6
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
20% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 10
0.71% more ownership
Funds ownership: 16.65% [Q1] → 17.36% (+0.71%) [Q2]
9% less funds holding
Funds holding: 57 [Q1] → 52 (-5) [Q2]
26% less capital invested
Capital invested by funds: $16.6M [Q1] → $12.3M (-$4.29M) [Q2]
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
EF Hutton Jason Kolbert 39% 1-year accuracy 22 / 56 met price target | 228%upside $10 | Buy Maintained | 30 Sept 2024 |
EF Hutton Jason Kolbert 39% 1-year accuracy 22 / 56 met price target | 228%upside $10 | Buy Maintained | 24 Sept 2024 |
HC Wainwright & Co. Yi Chen 36% 1-year accuracy 35 / 97 met price target | 130%upside $7 | Buy Reiterated | 17 Sept 2024 |
EF Hutton Jason Kolbert 39% 1-year accuracy 22 / 56 met price target | 228%upside $10 | Buy Maintained | 9 Sept 2024 |
EF Hutton Jason Kolbert 39% 1-year accuracy 22 / 56 met price target | 228%upside $10 | Buy Initiated | 7 Aug 2024 |
Financial journalist opinion
Based on 4 articles about ANIX published over the past 30 days
